✨ Free AI Report
Sundrug Co., Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Sundrug Co., Ltd.
Company Research

Sundrug Co., Ltd.: Business Overview, Financials & Competitive Analysis

Sundrug Co., Ltd. scores 6/10 on the AskCyborg Cyborg Score (Solid). Mature retail operator with defensive characteristics, offering dividend income and defensive positioning in a mature market segment, though limited growth dynamism. Sundrug demonstrates stable fundamentals with consistent earnings growth (1% annualized over 3 years), a strong balance sheet, and reliable dividend payments. However, share price underperformance relative to earnings.

What is Sundrug Co., Ltd.'s industry? Sundrug Co., Ltd. (sundrug.co.jp) operates in Retail Pharmacy & General Merchandise Distribution. AskCyborg classifies Sundrug Co., Ltd. under Retail Pharmacy & General Merchandise Distribution in its company registry.

Sundrug Co., Ltd. is a major Japanese retailer operating drug stores and discount stores across the nation. The company generates approximately ¥802 billion in annual revenue, with a market capitalization of approxima...

6/ 10Solid

Cyborg Score thesis

Mature retail operator with defensive characteristics, offering dividend income and defensive positioning in a mature market...

Read the full analyst-debate transcript →
Industry Retail Pharmacy & General Merchandise Distribution
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Sundrug Co., Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Sundrug Co., Ltd.

AskCyborg analysts argue the bull and bear cases for Sundrug Co., Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Sundrug Co., Ltd. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Sundrug Co., Ltd. Overview

Pro stress-test →

Sundrug Co., Ltd. is a major Japanese retailer operating drug stores and discount stores across the nation. The company generates approximately ¥802 billion in annual revenue, with a market capitalization of approximately ¥495 billion, positioning it as a significant player in Japan's retail pharmaceutical and general merchandise sectors.

Strategic Profile

Pro stress-test →

Sundrug maintains a dual-segment model: its Drug Store Business focuses on pharmaceutical products, cosmetics, and daily necessities, while its Discount Store Business offers food and household goods. The company leverages a widespread physical retail network to provide convenient consumer access and operates with stable profitability, though recent share price performance has lagged earnings growth.

Competitive Landscape

Pro stress-test →

Sundrug competes with other major Japanese pharmacy chains including Kusuri No Aoki Holdings, MatsukiyoCocokara, and Create SD Holdings. The company maintains competitive positioning through extensive store network coverage and diversified product offerings spanning pharmaceuticals to household goods, though faces pricing and convenience competition from larger retailers and e-commerce platforms.

Industry Context

Sundrug Co., Ltd. operates in Retail Pharmacy & General Merchandise Distribution.

Key facts

Founded: 1957 · Headquarters: Fuchu, Japan · Employees: 7,140 · Revenue: ¥801.81B · Market cap: ¥495.12B (~$3.3B USD)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Sundrug Co., Ltd..

  • Drug store segment is primary revenue driver at ¥459.6B, up from ¥437.95B year-prior, showing modest organic growth
  • Market cap of ¥495B with low volatility (2.16%) suggests investor perception of defensive, stable business model
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Oct 2025Employee count reached 7,140 employees as company continues stable operations
  • 2024Dividend yield improved to 3.09% with sustainable 49.45% payout ratio
  • +1 moreTrack every material event for Sundrug Co., Ltd. as it happens. Explore monitoring →
Get alerted when Sundrug Co., Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Pharmacy ChainMajor Japanese pharmacy chain operator→Pharmacy RetailerLarge-scale pharmacy and general merchandise retailer→Discount Store OperatorDiscount store and pharmacy operator in Japan→

Compare Sundrug Co., Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Sundrug Co., Ltd. operates in Retail Pharmacy & General Merchandise Distribution. See how the rest of the sector scores on the Cyborg framework.

Browse Retail Pharmacy & General Merchandise Distribution research →
NEW · MCP server

Ask your AI assistant about Sundrug Co., Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Sundrug Co., Ltd. and its top competitor on Cyborg Score”
“What did Sundrug Co., Ltd. do this quarter?”
“Is Sundrug Co., Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Sundrug Co., Ltd. do?+
Sundrug Co., Ltd. is a major Japanese retailer operating drug stores and discount stores across the nation. The company generates approximately ¥802 billion in annual revenue, with a market capitalization of approxima...
What is Sundrug Co., Ltd.'s Cyborg Score?+
Sundrug Co., Ltd. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Sundrug Co., Ltd.'s main competitors?+
Named competitors include Pharmacy Chain, Pharmacy Retailer, Discount Store Operator. The full competitive landscape is in the AskCyborg report.
How can I get the full Sundrug Co., Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Sundrug Co., Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Sundrug Co., Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.